Skip to main content
. Author manuscript; available in PMC: 2014 Sep 1.
Published in final edited form as: Mol Cancer Ther. 2013 Jul 3;12(9):1896–1905. doi: 10.1158/1535-7163.MCT-12-1243

Figure 3.

Figure 3

Inhibition of endogenous phosphorylation of c-Myc. (A) Western blot analysis of SKBR3 cells after NTZ treatment was performed using phospho c-Myc, c-Myc protein and β-actin antibodies. (B) NTZ induced dose dependent inhibition of phospho c-Myc level in all three tumor cell lines, SKBR3 (IC50=122nM), lymphoma (IC50=440nM) and sarcoma cells (IC50=12nM). The fold-change of phospho c-Myc level was plotted against the log scale of NTZ concentration.